Filing Details
- Accession Number:
- 0001179110-11-003553
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-02-28 15:42:11
- Reporting Period:
- 2011-02-24
- Filing Date:
- 2011-02-28
- Accepted Time:
- 2011-02-28 15:42:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 815094 | Abiomed Inc | ABMD | Surgical & Medical Instruments & Apparatus (3841) | 042743260 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1021038 | A Henri Termeer | C/O Abiomed, Inc. 22 Cherry Hill Drive Danvers MA 01923 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 Par Value | Disposition | 2011-02-24 | 10,000 | $12.52 | 1,805,296 | No | 4 | S | Indirect | by Genzyme Corporation |
| Common Stock, $0.01 Per Value | Disposition | 2011-02-24 | 15,000 | $12.45 | 1,790,296 | No | 4 | S | Indirect | by Genzyme Corporation |
| Common Stock, $0.01 Par Value | Disposition | 2011-02-25 | 4,695 | $12.74 | 1,785,601 | No | 4 | S | Indirect | by Genzyme Corporation |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | by Genzyme Corporation |
| No | 4 | S | Indirect | by Genzyme Corporation |
| No | 4 | S | Indirect | by Genzyme Corporation |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock, $0.01 Par Value | 60,100 | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | $19.69 | 2001-08-09 | 2010-08-09 | 5,000 | 5,000 | Direct |
| Common Stock | Stock Option (right to buy) | $18.40 | 2002-08-08 | 2012-08-08 | 5,000 | 5,000 | Direct |
| Common Stock | Stock Option (right to buy) | $4.71 | 2003-08-06 | 2013-08-06 | 5,000 | 5,000 | Direct |
| Common Stock | Stock Option (right to buy) | $5.15 | 2004-08-13 | 2014-08-13 | 5,000 | 5,000 | Direct |
| Common Stock | Stock Option (right to buy) | $10.41 | 2005-08-11 | 2014-08-11 | 8,000 | 8,000 | Direct |
| Common Stock | Stock Option (right to buy) | $10.06 | 2006-08-09 | 2015-08-10 | 8,000 | 8,000 | Direct |
| Common Stock | Stock Option (right to buy) | $13.21 | 2007-08-08 | 2016-08-09 | 8,000 | 8,000 | Direct |
| Common Stock | Stock option (right to buy) | $12.69 | 2008-08-13 | 2017-08-08 | 8,000 | 8,000 | Direct |
| Common Stock | Stock Option (right to buy) | $18.63 | 2009-08-12 | 2018-08-13 | 8,000 | 8,000 | Direct |
| Common Stock | Stock Option (right to buy) | $7.67 | 2010-08-11 | 2019-08-12 | 12,000 | 12,000 | Direct |
| Common Stock | Stock Options (right to buy) | $9.99 | 2011-08-10 | 2020-08-11 | 12,000 | 12,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2010-08-09 | 5,000 | 5,000 | Direct |
| 2012-08-08 | 5,000 | 5,000 | Direct |
| 2013-08-06 | 5,000 | 5,000 | Direct |
| 2014-08-13 | 5,000 | 5,000 | Direct |
| 2014-08-11 | 8,000 | 8,000 | Direct |
| 2015-08-10 | 8,000 | 8,000 | Direct |
| 2016-08-09 | 8,000 | 8,000 | Direct |
| 2017-08-08 | 8,000 | 8,000 | Direct |
| 2018-08-13 | 8,000 | 8,000 | Direct |
| 2019-08-12 | 12,000 | 12,000 | Direct |
| 2020-08-11 | 12,000 | 12,000 | Direct |
Footnotes
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors.
- This option becomes exercisable in full on the date set forth in Table II, Column 6.
- The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purposes. The reporting person is the Chief Executive Officer of Genzyme Corporation.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- Grant to reporting person of option to buy shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $12.50 and $12.54. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $12.39 and $12.53. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $12.66 and $12.84. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
Billionaire Hedge Funds
